Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virology. May 12, 2015; 4(2): 105-112
Published online May 12, 2015. doi: 10.5501/wjv.v4.i2.105
Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons
Christopher Akolo, Florence Bada, Evaezi Okpokoro, Ogochukwu Nwanne, Sharon Iziduh, Eno Usoroh, Taofeekat Ali, Vivian Ibeziako, Olanrewaju Oladimeji, Michael Odo
Christopher Akolo, Population Services International, Washington, DC 20036, United States
Florence Bada, Evaezi Okpokoro, Ogochukwu Nwanne, Sharon Iziduh, Eno Usoroh, Taofeekat Ali, Vivian Ibeziako, Institute of Human Virology, Nigeria (IHVN), Plot 252, PO Box 9396, Abuja, Nigeria
Olanrewaju Oladimeji, Zankli Medical Center, Plot 1021, PO Box 7745, Abuja, Nigeria
Olanrewaju Oladimeji, Liverpool School of Tropical Medicine, Pembroke Place, L3 5QA Liverpool, United Kingdom
Michael Odo, Family Health International (FHI360), Plot 1073, Garki, Area 3| P.M.B. 44, Abuja, Nigeria
Author contributions: Akolo C and Bada F were both responsible for the conceptualization of this article; Akolo C, Bada F, Okpokoro E, Iziduh S, Usoroh E, Nwanne O, Ali T, Ibeziako V, Oladimeji O and Odo M all contributed equally to the writing, editing and final approval of this work.
Conflict-of-interest: The authors have no conflict of interest related to this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Christopher Akolo, MBBS, MSc, FWACP, Senior Technical Advisor HIV/TB, Population Services International, 1120 19th Street, N.W. Ste. 600, Washington, DC 20036, United States.
Telephone: +1-240-5810853
Received: October 23, 2014
Peer-review started: October 23, 2014
First decision: November 14, 2014
Revised: December 4, 2014
Accepted: February 9, 2015
Article in press: February 11, 2015
Published online: May 12, 2015
Core Tip

Core tip: To better inform healthcare providers, policy makers and human immunodeficiency virus-infected persons about isoniazid preventive therapy (IPT), this article summarizes the existing evidence in support of IPT including recommendations for scale-up of implementation globally.